Table 1.
Baseline Characteristics of IgG4-Positive and IgG4-Negative Patients with TED
| IgG4-positive TED (n = 64) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Definitive (n = 15) | Probable (n = 27) | Possible (n = 22) | All (n = 64) | IgG4-negative (n = 121) | P1 | P2 | P3 | P4 | P5 |
| Sex, Male:Female | 10:5 | 14:13 | 13:9 | 37:27 | 63:58 | 0.285 | 0.984 | 0.544 | 0.456 | 0.698 |
| Age at diagnosis, y | 53.40 ± 12.11 | 50.44 ± 9.29 | 55.91 ± 10.03 | 53.02 ± 10.37 | 47.45 ± 13.46 | 1.000 | 1.000 | 0.021 | 0.008 | 0.023 |
| Laterality, bilateral:unilateral | 14:1 | 26:1 | 22:0 | 62:2 | 109:12 | 1.000 | 0.512 | 0.260 | 0.171 | 0.341 |
| Smoking history, n (%) | 8 (53.3) | 10 (37.0) | 9 (40.9) | 27 (42.2) | 35 (28.9) | 0.105 | 0.407 | 0.263 | 0.069 | 0.214 |
| Severity (moderate-to-severe: sight-threatening) | 9:6 | 10:17 | 5:17 | 24:40 | 70:51 | 0.847 | 0.050 | 0.002 | 0.008 | 0.008 |
| Pre-operative CAS | 2.53 ± 1.73 | 2.04 ± 1.53 | 1.68 ± 1.49 | 2.03 ± 1.57 | 1.05 ± 1.16 | 0.003 | 0.007 | 0.318 | <0.001 | <0.001 |
| Pre-operative BCVA logMAR | 0.56 ± 0.78 | 0.59 ± 0.73 | 0.88 ± 0.76 | 0.68 ± 0.75 | 0.43 ± 0.60 | 1.000 | 1.000 | 0.023 | 0.026 | 0.023 |
| Duration of TED, mo | 42.33 ± 64.11 | 22.37 ± 23.67 | 19.23 ± 23.91 | 25.97 ± 37.68 | 31.18 ± 31.84 | 0.987 | 0.499 | 0.259 | 0.322 | 0.087 |
| History of steroid use, n (%) | 12 (80.0) | 19 (70.4) | 18 (81.8) | 49 (76.6) | 88 (72.7) | 0.770 | 0.805 | 0.370 | 0.571 | 0.737 |
| Initial thyroid function | ||||||||||
| Hyperthyroidism, n (%) | 12 (80.0) | 26 (96.3) | 18 (81.8) | 56 (87.5) | 103 (85.1) | 0.889 | 0.211 | 0.941 | 0.658 | 0.360 |
| Hypothyroidism, n (%) | 0 (0.0) | 1 (3.7) | 2 (9.1) | 3 (4.7) | 5 (4.1) | 1.000 | 1.000 | 0.649 | 1.000 | 0.589 |
| Euthyroidism, n (%) | 3 (20.0) | 0 (0.0) | 2 (9.1) | 5 (7.8) | 13 (10.7) | 0.532 | 0.159 | 1.000 | 0.522 | 0.183 |
| Hashimoto's thyroiditis, n (%) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 1 (1.6) | 0 (0.0) | 0.110 | NA | NA | 0.346 | 0.081 |
| Duration of thyroid disease, mo | 63.67 ± 66.62 | 34.11 ± 28.47 | 40.05 ± 59.96 | 42.14 ± 50.10 | 53.81 ± 60.38 | 1.000 | 0.657 | 1.000 | 0.207 | 0.278 |
| I-131 therapy history, n (%) | 2 (13.3) | 4 (14.8) | 4 (18.2) | 10 (15.6) | 29 (24.0) | 0.549 | 0.302 | 0.554 | 0.186 | 0.618 |
| Hypothyroidism after I-131 therapy, n (%) | 1 (50.0) | 3 (75.0) | 3 (75.0) | 7 (70.0) | 14 (48.3) | 1.000 | 0.639 | 0.639 | 0.412 | 0.678 |
P1, definitive IgG4-positive versus IgG4-negative; P2, probable IgG4-positive versus IgG4-negative; P3, possible IgG4-positive versus IgG4-negative; P4, all IgG4-positive versus IgG4-negative; P5, definitive IgG4-positive versus probable IgG4-positive versus possible IgG4-positive versus IgG4-negative.
Data are shown as the means plus/minus SDs. IgG4, immunoglobulin G4; TED, thyroid eye disease; CAS, clinical activity score; BCVA, best corrected visual acuity; NA, not applicable.
Significant P values are shown with bold characters.